Program
Acetaminophen
Also written as “Paracetamol”, “IV Acetaminophen” and “Experimental paracetamol formulation”.
Its studies are mostly in Pain · Pain, Postoperative · Migraine Disorders · Common Cold · Fever, led by 26 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 390 open or running | phase 4since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| GlaxoSmithKline | 240 open or running | phase 4since Feb 18, 2010 | Jun 2, 2006 | none ahead |
| Keenova Therapeutics | 110 open or running | phase 4since Feb 5, 2016 | Nov 14, 2006 | none ahead |
| Allodynic Therapeutics | 60 open or running | phase 3since Jun 8, 2017 | Feb 17, 2017 | none ahead |
| Novartis | 60 open or running | phase 4since Jun 19, 2007 | Jan 29, 2007 | none ahead |
| Sanofi | 41 open or running | phase 3since Feb 12, 2007 | Feb 12, 2007 | May 17, 2027phase 2 · NCT06647407 |
| Sun Pharmaceutical Industries | 40 open or running | no phasesince Feb 18, 2010 | Feb 18, 2010 | none ahead |
| AFT Pharmaceuticals | 30 open or running | phase 3since Aug 16, 2011 | Aug 16, 2011 | none ahead |
| Nevakar | 30 open or running | phase 2since Jul 8, 2019 | Jul 8, 2019 | none ahead |
| Angelini Pharma | 20 open or running | phase 2since Apr 9, 2015 | Apr 9, 2015 | none ahead |
| Baxter Healthcare | 20 open or running | phase 3since Nov 29, 2006 | Nov 29, 2006 | none ahead |
| Grünenthal | 20 open or running | phase 1since Apr 27, 2017 | Apr 27, 2017 | none ahead |
| Hamad Medical | 20 open or running | phase 4since Dec 12, 2019 | Jun 21, 2013 | none ahead |
| Laboratorios Silanes S.A. de C.V. | 20 open or running | phase 3since Mar 3, 2025 | Jun 15, 2022 | none ahead |
| sintetica-sa | 20 open or running | phase 2since Dec 23, 2015 | Dec 23, 2015 | none ahead |
| ascension-health | 10 open or running | phase 4since Aug 23, 2018 | Aug 23, 2018 | none ahead |
| AstraZeneca | 10 open or running | phase 1since Aug 24, 2018 | Aug 24, 2018 | none ahead |
| Boehringer Ingelheim | 10 open or running | phase 3since Jul 7, 2014 | Jul 7, 2014 | none ahead |
| Bristol-Myers Squibb | 10 open or running | phase 4since Jun 23, 2006 | Jun 23, 2006 | none ahead |
| Eurofarma Laboratorios | 10 open or running | phase 3since Oct 5, 2021 | Oct 5, 2021 | none ahead |
| HALEON | 10 open or running | phase 1since Feb 28, 2025 | Feb 28, 2025 | none ahead |
| Intarcia Therapeutics | 10 open or running | phase 1since Dec 21, 2015 | Dec 21, 2015 | none ahead |
| Par Health | 10 open or running | phase 1since Apr 1, 2008 | Apr 1, 2008 | none ahead |
| qc-kinetix-llc | 10 open or running | phase 2since Feb 6, 2023 | Feb 6, 2023 | none ahead |
| Reckitt | 10 open or running | phase 3since Oct 26, 2010 | Oct 26, 2010 | none ahead |
| rottapharm | 10 open or running | phase 3since May 9, 2005 | May 9, 2005 | none ahead |
Also a collaborator on its studies: nevakar-injectables-inc, cross-s-a, cross-research-s-a, premier-research-group-plc, aptuit, mds-pharma-services and pricara-unit-of-ortho-mcneil-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jun 23, 2011.
- Jun 23, 2020Phase 2 study in PainJohnson & Johnson · NCT04447040 · 304 enrolled · United States
- Jul 27, 2020Phase 2 study in Pain, PostoperativeNevakar · NCT04495283 · 87 enrolled · United States
- Oct 5, 2021Eurofarma Laboratorios's first study: phase 3 study in Common ColdNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT05118672 · 567 enrolled · Brazil
- Jun 15, 2022Laboratorios Silanes S.A. de C.V.'s first study: phase 1 study in PainNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT05428306 · 42 enrolled · Mexico
- Dec 27, 2022Phase 2 study in Migraine DisordersAllodynic Therapeutics · NCT05685225 · United States
- Feb 6, 2023qc-kinetix-llc's first study: phase 2 study in Osteoarthritis, KneeNew to qc-kinetix-llcqc-kinetix-llc · NCT05742763 · United States
- Feb 27, 2023Phase 3 study in PainJohnson & Johnson · NCT05761574 · 447 enrolled · United States
- Apr 25, 2023Phase 3 study in Orthodontic PainJohnson & Johnson · NCT05845008 · United States
- Apr 25, 2023Phase 1 study in Orthodontic PainJohnson & Johnson · NCT05844995 · 24 enrolled · United States
- May 11, 2023Phase 3 study in PainJohnson & Johnson · NCT05868122 · 143 enrolled · United States
- Jan 30, 2024Phase 2 study in Migraine DisordersAllodynic Therapeutics · NCT06245902 · 92 enrolled · United States
- Oct 16, 2024Phase 2 study in Meningococcal ImmunizationSanofi · NCT06647407 · 750 enrolled · Brazil, Czechia, Denmark and more
- Feb 28, 2025HALEON's first study: phase 1 study in FeverNew to HALEONHALEON · NCT06855576 · 54 enrolled · Germany
- Mar 3, 2025Phase 3 study in ArthralgiaLaboratorios Silanes S.A. de C.V. · NCT06863636 · 231 enrolled · Mexico
Ahead
- May 17, 2027Primary completion: phase 2 study in Meningococcal ImmunizationSanofi · NCT06647407
TargetBeta
“Cyclooxygenase inhibitor; Anandamide amidohydrolase inhibitor; Vanilloid receptor opener”ChEMBL 37, by rule
Studies
The newest 60 of 123 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06863636Arthralgia · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Oct 30, 2025 | 231 |
| NCT06855576Fever · Germany | 1 | Completed | HALEON | Apr 17, 2025 | 54 |
| NCT06647407Meningococcal Immunization · Brazil, Czechia, Denmark and more | 2 | Active, not recruiting | Sanofi | May 17, 2027 | 750 |
| NCT06245902Migraine Disorders · United States | 2 | Completed | Allodynic Therapeutics | Feb 8, 2018 | 92 |
| NCT05868122Pain · United States | 3 | Completed | Johnson & Johnson | May 25, 2024 | 143 |
| NCT05845008Orthodontic Pain · United States | 3 | Withdrawn | Johnson & Johnson | Jul 15, 2024 | 0 |
| NCT05844995Orthodontic Pain · United States | 1 | Completed | Johnson & Johnson | Feb 12, 2024 | 24 |
| NCT05761574Pain · United States | 3 | Completed | Johnson & Johnson | May 17, 2024 | 447 |
| NCT05742763Osteoarthritis, Knee · United States | 2 | Withdrawn | qc-kinetix-llc | Oct 7, 2024 | 0 |
| NCT05685225Migraine Disorders · United States | 2 | Withdrawn | Allodynic Therapeutics | Dec 2, 2025 | 0 |
| NCT05428306Pain · Mexico | 1 | Completed | Laboratorios Silanes S.A. de C.V. | Nov 6, 2018 | 42 |
| NCT05118672Common Cold · Brazil | 3 | Completed | Eurofarma Laboratorios | Aug 26, 2025 | 567 |
| NCT04495283Pain, Postoperative · United States | 2 | Completed | Nevakar | Nov 12, 2020 | 87 |
| NCT04447040Pain · United States | 2 | Completed | Johnson & Johnson | Apr 9, 2021 | 304 |
| NCT04265456Pain, Postoperative · United States | 1 | Completed | Nevakar | Jun 15, 2020 | 63 |
| NCT04230252Healthy · Korea, Republic of | 1 | Completed | Johnson & Johnson | Feb 10, 2020 | 30 |
| NCT04214691Healthy · Korea, Republic of | 1 | Completed | Johnson & Johnson | Jan 16, 2020 | 30 |
| NCT04199572Musculoskeletal Injury · Qatar | 4 | Completed | Hamad Medical | Feb 21, 2023 | 162 |
| NCT04018612Pain, Postoperative · United States | 2 | Completed | Nevakar | Jul 26, 2019 | 110 |
| NCT03879408Pain · United States | 2 | Completed | Johnson & Johnson | Nov 7, 2019 | 290 |
| NCT03649165Neurofibromatosis 1 · United States | 1 | Completed | AstraZeneca | Oct 21, 2018 | 24 |
| NCT03702023Post Electrophysiology Procedure Pain · United States | 4 | UNKNOWN | ascension-health | Jun 1, 2020 | 200 |
| NCT03428230Pain, Postoperative · Switzerland | 2 | Completed | sintetica-sa | Oct 22, 2019 | 60 |
| NCT03415243Common Cold · United States | 1 | Completed | GlaxoSmithKline | Mar 29, 2018 | 28 |
| NCT03368664Multiple Sclerosis · France, Italy, Poland and more | 3 | Terminated | Sanofi | May 4, 2021 | 16 |
| NCT03201393Radiculopathy · United States | 2 | Completed | Allodynic Therapeutics | Jul 26, 2018 | 12 |
| NCT03194555Headache · United States | 2 | Completed | Allodynic Therapeutics | Jul 26, 2018 | 12 |
| NCT03185143Migraine With and Without Aura · United States | 3 | Completed | Allodynic Therapeutics | May 7, 2018 | 36 |
| NCT03137030Opioid-Related Disorders · United States | 1 | Withdrawn | Grünenthal | Jan 2018 | 0 |
| NCT03137017Opioid-Related Disorders · United States | 1 | Withdrawn | Grünenthal | Nov 2017 | 0 |
| NCT03061734Migraine Disorders · United States | 2 | Completed | Allodynic Therapeutics | Feb 8, 2018 | 92 |
| NCT02974114Pain · United Kingdom | 4 | Terminated | GlaxoSmithKline | Feb 6, 2017 | 21 |
| NCT02902666Healthy | 1 | Completed | Angelini Pharma | May 2016 | 46 |
| NCT02848729Pain · United States | 4 | Completed | Keenova Therapeutics | Mar 2016 | 50 |
| NCT02735122Post Operative Dental Pain · United States | 3 | Completed | Johnson & Johnson | Oct 5, 2016 | 420 |
| NCT02746263Pain, Postoperative · United States | 4 | Terminated | Keenova Therapeutics | May 5, 2016 | 1 |
| NCT02689063Pain, Postoperative · United States | 3 | Completed | AFT Pharmaceuticals | Jun 30, 2017 | 276 |
| NCT02678416Pain · United States | 4 | Completed | Keenova Therapeutics | Jun 13, 2016 | 79 |
| NCT02678234Respiratory Tract Infections | 3 | Withdrawn | GlaxoSmithKline | Apr 1, 2017 | 0 |
| NCT02730364Respiratory Tract Infections | 3 | Withdrawn | GlaxoSmithKline | Apr 1, 2017 | 0 |
| NCT02654860Phase 1: Pain Management · Switzerland | 2 | Completed | sintetica-sa | Feb 2019 | 69 |
| NCT02641899Healthy · United States | 1 | Completed | Intarcia Therapeutics | Mar 2016 | 33 |
| NCT02583594Multiple Sclerosis, Chronic Progressive · Spain | 1 | Completed | Sanofi | Mar 2016 | 24 |
| NCT02422966Ductus Arteriosus, Patent · Italy | 2 | Completed | Angelini Pharma | Jan 2019 | 110 |
| NCT02320708Toothache · United States | 2 | Completed | Johnson & Johnson | Apr 30, 2015 | 240 |
| NCT02311881Pain · United States | 3 | Completed | GlaxoSmithKline | Feb 2016 | 960 |
| NCT02183688Migraine Disorders | 3 | Completed | Boehringer Ingelheim | Jan 2003 | 1,889 |
| NCT01973205Migraine Disorders · United States | 3 | Completed | Novartis | Jul 2014 | 900 |
| NCT01960114Toothache · United States | 2 | Completed | Johnson & Johnson | Apr 2014 | 403 |
| NCT01891435Fever · Qatar | – | Completed | Hamad Medical | Dec 2011 | 434 |
| NCT01842633Pain · United States | 3 | Terminated | GlaxoSmithKline | Mar 31, 2015 | 365 |
| NCT01822665Gastrointestinal Mucosal Damage · United States | 4 | Completed | GlaxoSmithKline | Jul 2012 | 28 |
| NCT01814878Pain, Postoperative | 3 | Completed | Johnson & Johnson | Jan 2011 | 320 |
| NCT01767428Fever | 1 | Completed | GlaxoSmithKline | Apr 2010 | 30 |
| NCT01728246Osteoarthritis · Philippines | 4 | Completed | Johnson & Johnson | May 2008 | 473 |
| NCT01686646Common Cold · United Kingdom | 3 | Completed | GlaxoSmithKline | Nov 2012 | 240 |
| NCT01635101Acute Pain · United States | 3 | Completed | Keenova Therapeutics | Aug 2015 | 197 |
| NCT01592227Pain · United States | 1 | Completed | GlaxoSmithKline | Dec 2009 | 30 |
| NCT01568749Agnosia · United States | 1 | Completed | GlaxoSmithKline | Aug 2009 | 14 |
| NCT01551836Healthy Volunteer · United Kingdom | 1 | Completed | GlaxoSmithKline | Jun 2009 | 12 |
How it is read
Names in the registry
- “Acetaminophen”, 24 entries
- “Paracetamol”, 10 entries
- “IV Acetaminophen”, 10 entries
- “Experimental paracetamol formulation”, 5 entries
- “acetaminophen”, 5 entries
Conditions, from the studies’ own filings
- Pain, 28 studies
- Pain, Postoperative, 13 studies
- Migraine Disorders, 8 studies
- Common Cold, 7 studies
- Fever, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.